Kivo Health raises $10M to treat lung disease at home
What's the deal? Kivo HealthDealroom has a profile for this one. Try Dealroom →, a telehealth provider focused on lung diseases, raised a $10 million Series A led by Allumia VenturesDealroom has a profile for this one. Try Dealroom →, chief executive officer Victor Sadauskas told Axios Pro. Y Combinator, MassMutual VenturesDealroom has a profile for this one. Try Dealroom →, Liquid 2 Ventures, and UCSF Rosenman Institute also backed the round.
What's the endgame? The San Francisco startup runs a nine-week virtual program that pairs COPD patients with licensed respiratory therapists for pulmonary rehabilitation from home. It targets a gap in care: in-person rehab is hard for many patients to reach.
By the numbers: Kivo says COPD affects roughly 1 in 9 Medicare Advantage members, and high-risk cases cost 2.9 times more than members without the disease. It projects a 3.1x return for health plans, or nearly $10 million in savings per 100,000 members.
Why now? Managing chronic respiratory conditions outside hospitals is driving deal activity. In August 2026, Wellinks raised $10 million for remote monitoring and virtual care in chronic respiratory disease.
What could go wrong? Kivo's significance hinges on evidence of clinical outcomes and uptake from payers or health systems. Both remain the key hurdles for home-based respiratory care.
The signal: The round reflects steady investor and provider interest in moving respiratory care into the home, where access barriers keep many patients from standard pulmonary rehab.
Read more: Axios
Image credit: Generated with Gemini
